$-0.02 EPS Expected for Oncolytics Biotech Inc. (ONCYF)
March 4, 2018 – By Henry Gaston
Analysts expect Oncolytics Biotech Inc. (OTCMKTS:ONCYF) to report $-0.02 EPS on March, 9.They anticipate $0.01 EPS change or 33.33 % from last quarter’s $-0.03 EPS. After having $-0.02 EPS previously, Oncolytics Biotech Inc.’s analysts see 0.00 % EPS growth. The stock decreased 3.61% or $0.02203 during the last trading session, reaching $0.58797. About 135,980 shares traded. Oncolytics Biotech Inc. (OTCMKTS:ONCYF) has 0.00% since March 4, 2017 and is . It has underperformed by 16.70% the S&P500.
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company has market cap of $82.91 million. The firm is developing REOLYSIN, a systemically administered immune-oncology viral agent for the treatment of solid tumors and hematological malignancies. It currently has negative earnings.
Another recent and important Oncolytics Biotech Inc. (OTCMKTS:ONCYF) news was published by Fool.com which published an article titled: “This High-Risk, High-Reward Biotech Is Worth a Look” on June 25, 2013.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.